Department of Medicine, Rush University Medical Center, Chicago, Illinois, USA.
Harvard Medical School, Division of Nephrology, Massachusetts General Hospital, Charlestown, Massachusetts, USA.
J Clin Invest. 2019 Apr 2;129(5):1946-1959. doi: 10.1172/JCI124793.
Soluble urokinase plasminogen activator receptor (suPAR) is an immune-derived circulating signaling molecule that has been implicated in chronic kidney disease, such as focal segmental glomerulosclerosis (FSGS). Typically, native uPAR (isoform 1) translates to a 3-domain protein capable of binding and activating integrins, yet the function of additional isoforms generated by alternative splicing is unknown. Here, we characterized mouse uPAR isoform 2 (msuPAR2), encoding domain I and nearly one-half of domain II, as a dimer in solution, as revealed by 3D electron microscopy structural analysis. In vivo, msuPAR2 transgenic mice exhibited signs of severe renal disease characteristic of FSGS with proteinuria, loss of kidney function, and glomerulosclerosis. Sequencing of the glomerular RNAs from msuPAR2-Tg mice revealed a differentially expressed gene signature that includes upregulation of the suPAR receptor Itgb3, encoding β3 integrin. Crossing msuPAR2-transgenic mice with 3 different integrin β3 deficiency models rescued msuPAR2-mediated kidney function. Further analyses indicated a central role for β3 integrin and c-Src in msuPAR2 signaling and in human FSGS kidney biopsies. Administration of Src inhibitors reduced proteinuria in msuPAR2-transgenic mice. In conclusion, msuPAR2 may play an important role in certain forms of scarring kidney disease.
可溶性尿激酶型纤溶酶原激活物受体(suPAR)是一种免疫衍生的循环信号分子,与慢性肾脏病有关,如局灶节段性肾小球硬化症(FSGS)。通常,天然 uPAR(同种型 1)翻译为 3 个结构域的蛋白质,能够结合和激活整合素,但通过选择性剪接产生的其他同种型的功能尚不清楚。在这里,我们将小鼠 uPAR 同种型 2(msuPAR2)描述为一种二聚体,它编码结构域 I 和近一半的结构域 II,这是通过 3D 电子显微镜结构分析揭示的。在体内,msuPAR2 转基因小鼠表现出与 FSGS 特征性的严重肾脏疾病的迹象,包括蛋白尿、肾功能丧失和肾小球硬化。对 msuPAR2-Tg 小鼠肾小球 RNA 的测序揭示了一个差异表达的基因特征,包括 suPAR 受体 Itgb3 的上调,其编码 β3 整合素。将 msuPAR2 转基因小鼠与 3 种不同的β3 整合素缺陷模型杂交,挽救了 msuPAR2 介导的肾功能。进一步的分析表明,β3 整合素和 c-Src 在 msuPAR2 信号转导和人类 FSGS 肾活检中起核心作用。Src 抑制剂的给药减少了 msuPAR2 转基因小鼠的蛋白尿。总之,msuPAR2 可能在某些形式的瘢痕性肾脏疾病中发挥重要作用。